Logo image of VALN

VALNEVA SE - ADR (VALN) Stock Fundamental Analysis

NASDAQ:VALN - Nasdaq - US92025Y1038 - ADR - Currency: USD

5.81  0 (0%)

Fundamental Rating

3

VALN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. VALN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, VALN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

VALN had negative earnings in the past year.
In the past year VALN has reported a negative cash flow from operations.
In the past 5 years VALN always reported negative net income.
In multiple years VALN reported negative operating cash flow during the last 5 years.
VALN Yearly Net Income VS EBIT VS OCF VS FCFVALN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

VALN has a Return On Assets of 7.48%. This is amongst the best in the industry. VALN outperforms 93.51% of its industry peers.
VALN's Return On Equity of 20.65% is amongst the best of the industry. VALN outperforms 96.40% of its industry peers.
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
VALN Yearly ROA, ROE, ROICVALN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

VALN has a better Profit Margin (15.08%) than 94.05% of its industry peers.
VALN's Gross Margin of 41.01% is fine compared to the rest of the industry. VALN outperforms 74.77% of its industry peers.
VALN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 15.08%
GM 41.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
VALN Yearly Profit, Operating, Gross MarginsVALN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

VALN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VALN has more shares outstanding
The number of shares outstanding for VALN has been increased compared to 5 years ago.
Compared to 1 year ago, VALN has an improved debt to assets ratio.
VALN Yearly Shares OutstandingVALN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VALN Yearly Total Debt VS Total AssetsVALN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.22, we must say that VALN is in the distress zone and has some risk of bankruptcy.
VALN's Altman-Z score of 0.22 is fine compared to the rest of the industry. VALN outperforms 62.34% of its industry peers.
A Debt/Equity ratio of 1.06 is on the high side and indicates that VALN has dependencies on debt financing.
VALN has a worse Debt to Equity ratio (1.06) than 77.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Altman-Z 0.22
ROIC/WACCN/A
WACC8.49%
VALN Yearly LT Debt VS Equity VS FCFVALN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 2.61 indicates that VALN has no problem at all paying its short term obligations.
VALN's Current ratio of 2.61 is on the low side compared to the rest of the industry. VALN is outperformed by 68.47% of its industry peers.
A Quick Ratio of 2.14 indicates that VALN has no problem at all paying its short term obligations.
With a Quick ratio value of 2.14, VALN is not doing good in the industry: 72.07% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.61
Quick Ratio 2.14
VALN Yearly Current Assets VS Current LiabilitesVALN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for VALN have decreased strongly by -184.21% in the last year.
VALN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.86%.
Measured over the past years, VALN shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
Revenue 1Y (TTM)17.86%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%

3.2 Future

VALN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 119.91% yearly.
VALN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.84% yearly.
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue Next Year6.9%
Revenue Next 2Y17.55%
Revenue Next 3Y26.72%
Revenue Next 5Y24.84%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VALN Yearly Revenue VS EstimatesVALN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
VALN Yearly EPS VS EstimatesVALN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VALN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VALN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VALN Price Earnings VS Forward Price EarningsVALN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VALN Per share dataVALN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

VALN's earnings are expected to grow with 119.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.87%
EPS Next 3Y119.91%

More info and screens

0

5. Dividend

5.1 Amount

VALN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE - ADR

NASDAQ:VALN (7/3/2025, 8:15:29 PM)

5.81

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-12 2025-08-12
Inst Owners23.31%
Inst Owner Change-6.13%
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap494.04M
Analysts83.33
Price Target17.26 (197.07%)
Short Float %0%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31.52%
Min EPS beat(2)-115.24%
Max EPS beat(2)52.2%
EPS beat(4)2
Avg EPS beat(4)-8.58%
Min EPS beat(4)-115.24%
Max EPS beat(4)72.74%
EPS beat(8)4
Avg EPS beat(8)-10.16%
EPS beat(12)5
Avg EPS beat(12)-55.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.78%
Max Revenue beat(2)1.77%
Revenue beat(4)1
Avg Revenue beat(4)-7.74%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)1.77%
Revenue beat(8)4
Avg Revenue beat(8)-2.47%
Revenue beat(12)6
Avg Revenue beat(12)43.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.61%
PT rev (3m)6.82%
EPS NQ rev (1m)11.18%
EPS NQ rev (3m)13.71%
EPS NY rev (1m)1.72%
EPS NY rev (3m)16.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.69
P/FCF N/A
P/OCF N/A
P/B 2.31
P/tB 2.69
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS3.44
BVpS2.51
TBVpS2.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 20.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 15.08%
GM 41.01%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.96%
Cap/Sales 6.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.61
Quick Ratio 2.14
Altman-Z 0.22
F-Score5
WACC8.49%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.63%
EPS Next Y-597.38%
EPS Next 2Y-69.87%
EPS Next 3Y119.91%
EPS Next 5YN/A
Revenue 1Y (TTM)17.86%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%50.31%
Revenue Next Year6.9%
Revenue Next 2Y17.55%
Revenue Next 3Y26.72%
Revenue Next 5Y24.84%
EBIT growth 1Y82.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-262.99%
EBIT Next 3Y35.74%
EBIT Next 5Y30.38%
FCF growth 1Y61.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.85%
OCF growth 3YN/A
OCF growth 5YN/A